Published in Clin Pharmacokinet on June 01, 2016
Low caspofungin exposure in patients in the Intensive Care Unit. Antimicrob Agents Chemother (2016) 0.75
Pharmacokinetics of Anidulafungin in critically ill patients in the Intensive Care Unit with suspected or proven invasive fungal infections. Antimicrob Agents Chemother (2016) 0.75
Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration. Clin Pharmacokinet (2016) 0.75
Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients. Clin Pharmacokinet (2017) 0.75
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
A general model for the origin of allometric scaling laws in biology. Science (1997) 24.91
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
International study of the prevalence and outcomes of infection in intensive care units. JAMA (2009) 11.57
Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med (2002) 9.21
Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed (1999) 8.87
PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed (2005) 6.36
Body mass index is associated with hospital mortality in critically ill patients: an observational cohort study. Crit Care Med (2013) 6.16
Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis (2012) 5.83
Quantification of lean bodyweight. Clin Pharmacokinet (2005) 3.59
Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat (2011) 3.40
Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet (2009) 2.92
Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis (2004) 2.81
Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol (2009) 2.47
Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed (2010) 2.34
Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother (2005) 2.07
In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother (2010) 1.88
A pharmacokinetic standard for babies and adults. J Pharm Sci (2013) 1.58
A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis (2009) 1.54
High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant (2007) 1.48
In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother (2008) 1.28
Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother (2007) 1.28
The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev (2014) 1.14
Echinocandin pharmacodynamics: review and clinical implications. J Antimicrob Chemother (2010) 0.95
Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. Antimicrob Agents Chemother (2011) 0.95
Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations. J Clin Pharmacol (2007) 0.92
Pharmacokinetics of caspofungin in ICU patients. J Antimicrob Chemother (2014) 0.91
Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother (2011) 0.91
Phase II dose escalation study of caspofungin for invasive Aspergillosis. Antimicrob Agents Chemother (2011) 0.87
Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths. Antimicrob Agents Chemother (2013) 0.87
A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. J Antimicrob Chemother (2014) 0.85
Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis. Antimicrob Agents Chemother (2013) 0.85
Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients. Clin Pharmacokinet (2017) 0.75
Suboptimal dosing of fluconazole in critically ill patients - time to rethink dosing. Antimicrob Agents Chemother (2020) 0.75
Reduced rate of intensive care unit acquired gram-negative bacilli after removal of sinks and introduction of 'water-free' patient care. Antimicrob Resist Infect Control (2017) 0.75